This technology describes polyclonal antibodies for immunohistochemical analysis of prostate carcinoma tissues.
Early detection of prostate cancer is key to successful treatment. Current methods for detection of cancer typically require a physical exam or the detection of prostate-specific antigen (PSA) in the blood. However, a biopsy is often still needed to confirm diagnosis and determine treatment options. As such, there is a need for targeted antibodies for immunohistochemical analysis that can diagnose and classify prostate cancer for personalized treatment.
This technology provides polyclonal antibodies against the Nkx3.1 homeobox gene product for targeted detection and analysis of prostate carcinoma tissues. Loss of function of NKx3.1 in mice is associated with loss of function of the Pten tumor suppressor gene linked to cancer progression. Consequently, the absence of NKx3.1 protein expression may indicate early human prostate carcinogenesis and could be employed as a diagnostic test for prostate cancer. This technology provides antibodies against Nkx3.1 that could be used for diagnosing loss of NKx3.1 expression in immunohistochemical analysis or other bioassays.
IR 2739
Licensing Contact: Joan Martinez